Table 2
From the following article
India's health biotech sector at a crossroads
Sarah E Frew, Rahim Rezaie, Stephen M Sammut, Monali Ray, Abdallah S Daar & Peter A Singer
Nature Biotechnology 25, 403 - 417 (2007)
doi:10.1038/nbt0407-403
Table 2. Subsidiaries, joint ventures and research groups for companies interviewed
| Company Name | Subsidiary or joint venture |
|---|---|
ICICI, Industrial Credit and Investment Corporation of India. | |
| Avestha Gengraine Technologies | JV with Meditab Specialties (an affiliate of Cipla) called Avesta Biotherapeutics and Research (Bangalore) was established in 2005 for pilot and commercial scale manufacturing of biotherapeutics products. Avesta Nordic (Bangalore) was established as a joint venture with the Center for Clinical and Basic Research (CCRB, Denmark) and IFU, a Danish investment fund to develop nutritional bioactive products for osteoporosis. Avesta Good Earth Foods was formed when Avesthagen acquired Good Earth Foods. This company sells nutraceuticals such as cereals and energy bars. Avesthagen was set up in 2003/04 as a subsidiary in San Diego |
| Bharat Serums & Vaccines (BSV) | BSV BioSciences subsidiary in San Jose, involved in early development of biotech products. Aims to eventually have regulatory capabilities. Joint venture with Zydus Cadila, one of the leading pharmaceutical companies in India, for the commercialization of a BSV's novel anticancer drug |
| Biocon | Syngene (subsidiary). Contract research for other companies. Clinigene (subsidiary). Contract clinical trials for major multinational corporations. Joint venture with the research institute CIMAB (Havana, Cuba) to develop antibodies and cancer vaccines. Recently acquired the US-based Nobex Corporation |
| Dr. Reddy's Laboratories | Perlecan Pharma was created in 2005 by Dr. Reddy's (with funding largely from Citigroup Venture and ICICI Venture), and although an independent company, will be involved in clinical drug development and out-licensing of Dr. Reddy's new drug candidates. Discovery unit in Atlanta (US). Agreement to purchase Roche's API business in Cuernavaca, Mexico. Joint venture with a company in China for marketing purposes |
| GangaGen Biotechnologies | GangaGen Biotechnologies is itself a subsidiary of GangaGen based in the US. GangaGen Life Sciences (Canada) is another subsidiary; works on development of phage-based products for eliminating human pathogens in food, animals and the environment |
| Indian Immunologicals | IndiaGen (joint venture in the business of animal breeding and genetics advisory services to improve productivity of milch cattle) |
| Nicholas Piramal India | WellQuest conducts clinical trials at the Wellspring Hospital in Mumbai. Pathlabs NPIL (majority stake in three pathlabs). Pathology and diagnostic labs, and an infertility center. Boots Piramal Healthcare. Joint venture between UK-based Boots and Nicholas Piramal India focusing on over the counter pharmaceutical segment. Allergen India is involved in ophthalmology solutions for the Indian market |
| Panacea Biotec | Joint venture (Chiron-Panacea Vaccines) for development and marketing of combination vaccines with Novartis Vaccines (UK). The venture currently markets five vaccines including some combination vaccines against Hep-B, Hib and DPT |
| Reliance Life Sciences | Reliance Clinical Services. A contract research organizations organization |
| Shantha Biotechnics | Shantha West (US subsidiary). Research on monoclonal antibodies for cancer treatment |
| Wockhardt | Wockhardt USA. Regulatory and intellectual property rights involved in generic pharmaceuticals in the UK and has a wholly owned subsidiary in Brazil. Majority-owned companies in South Africa and Mexico and marketing offices elsewhere. Joint venture with Representaciones E Investigaciones Medicas de C.V. (Mexico City, Mexico). Joint venture with Pharma Dynamics (Tokai, South Africa) to work on formulation for diabetes |
